How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion Pharmaceuticals (RXRX) ended the recent trading session at $4.98, demonstrating a +1.32% change from the preceding day's closing price. The stock's change was more than the S&P 500's daily ...

In this article, we will be taking a look at the Top 10 AI-Powered Biotech Stocks to Buy Now. Recursion Pharmaceuticals, Inc. is one of them. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), a ...

Oracle India employees are experiencing heightened anxiety due to recent layoffs, particularly within the Oracle Cloud Infrastructure (OCI) division. Affected employees report abrupt terminations via ...

Oracle’s meteoric rise continues to defy expectations. With a 36% surge following its latest earnings and a cumulative 3x gain since early 2023, the enterprise software giant is rewriting the playbook ...

A version of this story appeared in CNN Business’ Nightcap newsletter. To get it in your inbox, sign up for free here. The catalyst wasn’t a flashy product rollout or a surprise earnings beat — in ...

Oracle’s ORCL remaining performance obligations for the first quarter increased 359% to $455 billion, primarily due to expanding relationships with large language model providers. Management also ...

Oracle's stock surged 36% after reporting record future revenue obligations. Jefferies sees more upside, lifting its stock price target to $360 on cloud and AI growth. Analysts point to Oracle's ...